Sensidose AB
Sensidose AB is a pharmaceutical company that has developed an innovative new system for individualized dosing of pharmaceutical tablets, allowing for fine-tuned, precision drug therapy. The system is composed of “micro”- tablets, sub-pharmaceutical units of tablets. The correct dose is achieved by dosing a certain number of tablets. The “micro”- tablets are retrieved using an automated dispenser. The dispenser has an inbuilt alarm, delivers doses at the programmed time point, and registers all doses delivered as well as disease symptoms with the help of easy to use scales. The company’s technology is expected to have the potential to reduce side effects and contribute to increased quality of life for the patient.
Company details
Find locations served, office locations
- Business Type:
- Technology
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Internationally (various countries)
This company also provides solutions for other industrial applications.
Please, visit the following links for more info:
About us
Sensidose AB is a pharmaceutical company that has developed a system for individualized dosing of tablets, a medical treatment using a dosing device pre-programmed for the patient. The system consists of tablets, containing low dose in each individual tablet. The correct dose is obtained by dosing a specific number of tablets. The tablets are dispensed using an electronic dispenser, programmed by the healthcare provider. The dispenser has a built-in alarm, delivers doses at the preset times and registers all doses delivered and also disease symptoms using rating scales that are easy to use. The company’s technology does not affect the course of the disease but treats the symptoms of the disease.
History and Founders
The history behind Sensidose
The idea behind Sensidose started already in the mid 1990’s. The founders Professors Sten-Magnus Aquilonius and Christer Nyström, both from Uppsala University, were previously active in the company NeoPharma.
Neopharma developed a method for the continuous delivery of levodopa directly to the small intestine with the help of a pump and a specifically developed gel (Duodopa®).
This treatment method, gave a very smooth, controllable and adjustable levels of levodopa in the blood. Duodopa has proven to be an appreciated addition to the treatment option for patients in the late phase of Parkinson’s disease. The founders realized that, even if you orally cannot achieve a continuous intake of levodopa, similarly as you can do with Duodopa® it should, with the help of micro-tablets and a more frequent and individualized treatment, be possible to improve care for patients in an earlier phase of the disease.
Sensidose was founded in 1998 to realize this possibility, however, it took until 2008 for the development to take off.
Founders
Sten-Magnus Aquilonius and Christer Nyström founded Sensidose in 1998.
Sten-Magnus Aquilonius is professor emeritus at the Department of Neuroscience and Christer Nyström is former professor of Galenic Pharmacy at Uppsala University. Both founders were involved in the development of the medicine Duodopa® within the Uppsala company Neopharma.
Duodopa was a new concept for the treatment of severely ill parkinsonian patients based upon the principle of CDS, Continuous Dopaminergic Stimulation, hence a stable, continuous supply of levodopa by delivering the medicine directly to intestinal sites where the drug is taken up and thereby avoiding troublesome fluctuations of levodopa that results in clinical unwanted effects. Duodopa treatment allows for individual fine tuning of the dose to optimize treatment.
To enable individualized dosing of oral tablets is the idea behind Sensidose. By means of microtablets, containing smaller subunits of levodopa, it should be possible to fine tune pharmacotherapy much in the way as is done with Duodopa, but without an invasive procedure.
Using microtablets it should be possible to treat also patients with advanced Parkinsons especiallycially when the “therapeutic window” is narrow and where standard medication is suboptimal. To facilitate individualized dosing it was evident that a dipsesing device coupled with an electronic diary was needed.
Microtablets and individualized dosing are foreseen to be of importance in several other conditions such as pain treatment, epilepsy, in pediatrics and oncology.